These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 38180851

  • 1. Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.
    Hoffman RM, Brummel S, Ziemba L, Chinula L, McCarthy K, Fairlie L, Jean-Philippe P, Chakhtoura N, Johnston B, Krotje C, Nematadzira TG, Nakayiwa F, Ndyanabangi V, Hanley S, Theron G, Violari A, João E, Correa MD, Hofer CB, Navanukroh O, Aurpibul L, Nevrekar N, Zash R, Shapiro R, Stringer JSA, Currier JS, Sax P, Lockman S, IMPAACT 2010/VESTED Study Team .
    Clin Infect Dis; 2024 Jun 14; 78(6):1617-1628. PubMed ID: 38180851
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, Jean-Philippe P, Johnston B, Krotje C, Fairlie L, Hoffman RM, Sax PE, Moyo S, Chakhtoura N, Stringer JS, Masheto G, Korutaro V, Cassim H, Mmbaga BT, João E, Hanley S, Purdue L, Holmes LB, Momper JD, Shapiro RL, Thoofer NK, Rooney JF, Frenkel LM, Amico KR, Chinula L, Currier J, IMPAACT 2010/VESTED Study Team and Investigators.
    Lancet; 2021 Apr 03; 397(10281):1276-1292. PubMed ID: 33812487
    [Abstract] [Full Text] [Related]

  • 3. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
    Asif S, Baxevanidi E, Hill A, Venter WDF, Fairlie L, Masenya M, Serenata C, Sokhela S, Chandiwana N.
    AIDS; 2021 Dec 15; 35(Suppl 2):S117-S125. PubMed ID: 34261099
    [Abstract] [Full Text] [Related]

  • 4. Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial.
    Masheto G, Brummel SS, Ziemba L, Shepherd J, Mbengeranwa T, Igawa L, Coletti A, Mukura D, Rossouw L, Theron G, Krotje C, Jean-Philippe P, Chakhtoura N, Cassim H, Mathiba SR, Maena J, Murtaugh W, Fairlie L, Currier J, Hoffman R, Chinula L, Sax PE, Stranix-Chibanda L, Lockman S, IMPAACT 2010/VESTED Study Team and Investigators.
    J Acquir Immune Defic Syndr; 2024 Oct 01; 97(2):172-179. PubMed ID: 39250651
    [Abstract] [Full Text] [Related]

  • 5. Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa.
    Chandiwana NC, Chersich M, Venter WDF, Akpomiemie G, Hill A, Simmons B, Lockman S, Serenata CM, Fairlie L, Moorhouse MA.
    AIDS; 2021 Feb 02; 35(2):205-211. PubMed ID: 33086234
    [Abstract] [Full Text] [Related]

  • 6. Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial.
    Wang R, Sun L, Wang X, Zhai Y, Wang L, Ma P, Wu C, Zhou Y, Chen R, Wang R, Zhang F, Hua W, Li A, Xia W, Gao Y, Li R, Lv S, Shao Y, Cao Y, Zhang T, Wu H, Cai C, Dai L.
    Clin Infect Dis; 2024 Jul 19; 79(1):169-176. PubMed ID: 38236137
    [Abstract] [Full Text] [Related]

  • 7. Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa.
    Manne-Goehler J, Fabian J, Sokhela S, Akpomiemie G, Rahim N, Lalla-Edward ST, Brennan AT, Siedner MJ, Hill A, Venter WDF.
    J Int AIDS Soc; 2024 Jul 19; 27(7):e26268. PubMed ID: 38978403
    [Abstract] [Full Text] [Related]

  • 8. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
    Orkin C, Antinori A, Rockstroh JK, Moreno-Guillén S, Martorell CT, Molina JM, Lazzarin A, Maggiolo F, Yazdanpanah Y, Andreatta K, Huang H, Hindman JT, Martin H, Pozniak A.
    AIDS; 2024 Jun 01; 38(7):983-991. PubMed ID: 38349226
    [Abstract] [Full Text] [Related]

  • 9. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
    Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, Serenata C, Akpomiemie G, Qavi A, Chandiwana N, Norris S, Chersich M, Clayden P, Abrams E, Arulappan N, Vos A, McCann K, Simmons B, Hill A.
    N Engl J Med; 2019 Aug 29; 381(9):803-815. PubMed ID: 31339677
    [Abstract] [Full Text] [Related]

  • 10. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
    Ruderman SA, Crane HM, Nance RM, Whitney BM, Harding BN, Mayer KH, Moore RD, Eron JJ, Geng E, Mathews WC, Rodriguez B, Willig AL, Burkholder GA, Lindström S, Wood BR, Collier AC, Vannappagari V, Henegar C, Van Wyk J, Curtis L, Saag MS, Kitahata MM, Delaney JAC.
    J Acquir Immune Defic Syndr; 2021 Mar 01; 86(3):339-343. PubMed ID: 33148997
    [Abstract] [Full Text] [Related]

  • 11. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
    Gan L, Xie X, Fu Y, Yang X, Ma S, Kong L, Song C, Song Y, Ren T, Long H.
    BMC Infect Dis; 2024 Jun 06; 24(1):565. PubMed ID: 38844855
    [Abstract] [Full Text] [Related]

  • 12. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial.
    Jamieson L, Serenata C, Makhubele L, Sokhela S, Mashabane N, Akpomiemie G, Johnson LF, Venter WDF, Meyer-Rath G.
    AIDS; 2021 Dec 15; 35(Suppl 2):S173-S182. PubMed ID: 34848584
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
    Bosch B, Akpomiemie G, Chandiwana N, Sokhela S, Hill A, McCann K, Qavi A, Mirchandani M, Venter WDF.
    Clin Infect Dis; 2023 Apr 17; 76(8):1492-1495. PubMed ID: 36519389
    [Abstract] [Full Text] [Related]

  • 15. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
    Acosta RK, Willkom M, Andreatta K, Liu H, Martin R, Parvangada A, Martin H, Collins S, White KL.
    J Acquir Immune Defic Syndr; 2020 Nov 01; 85(3):363-371. PubMed ID: 32701823
    [Abstract] [Full Text] [Related]

  • 16. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A.
    Lancet HIV; 2020 Oct 01; 7(10):e666-e676. PubMed ID: 33010240
    [Abstract] [Full Text] [Related]

  • 17. Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens.
    Cindi Z, Maartens G, Bradford Y, Venter WDF, Sokhela S, Chandiwana NC, Haas DW, Sinxadi P.
    J Acquir Immune Defic Syndr; 2021 Jul 01; 87(3):1002-1009. PubMed ID: 33625064
    [Abstract] [Full Text] [Related]

  • 18. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
    Davey S, Ajibola G, Maswabi K, Sakoi M, Bennett K, Hughes MD, Isaacson A, Diseko M, Zash R, Batlang O, Moyo S, Lockman S, Lichterfeld M, Kuritzkes DR, Makhema J, Shapiro R.
    J Acquir Immune Defic Syndr; 2020 Jul 01; 84(3):235-241. PubMed ID: 32195745
    [Abstract] [Full Text] [Related]

  • 19. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
    Giacomelli A, Conti F, Pezzati L, Oreni L, Ridolfo AL, Morena V, Bonazzetti C, Pagani G, Formenti T, Galli M, Rusconi S.
    BMC Infect Dis; 2021 Jun 22; 21(1):595. PubMed ID: 34157984
    [Abstract] [Full Text] [Related]

  • 20. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A, AI266073 Study Group.
    J Acquir Immune Defic Syndr; 2009 Jun 01; 51(2):163-74. PubMed ID: 19357529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.